MedTrace Logo

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

NCT00335322 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 329

Last updated 2019-09-26

Study results available
· View outcomes & findings →

Summary

In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with tenofovir and emtricitabine or tenofovir and emtricitabine combined with zidovudine and abacavir, as assessed by change from baseline plasma HIV-1 RNA viral load.

Conditions

  • Human Immunodeficiency Virus (HIV)

Interventions

DRUG

Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)

Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily

DRUG

Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)

Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)

DRUG

Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)

Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • David A Cooper, AO DSc MD FRACP FRCPA FRCP · Kirby Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2011-03-31
Completion
2011-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335322 on ClinicalTrials.gov